• Home
  • Search Results

Search Results

Kidneys and Liver
Transplant
75 studies match your search
Open

IgA Nephropathy Microbiome Study

The purpose of this study is to compare diet (record of the foods you eat), gut microbiome (stool sample), and cells (blood sample) in adults with IgA Nephropathy (IgAN) and compare with adults with focal segmental glomerulosclerosis (FSGS) and adults with no history of medical problems. The information we learn by doing this study may help us understand how we might be able to target the microbiome to better understand the disease process and potentially help us develop new therapies in the future.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Kidneys and Liver
  • Microbiome
Open

A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

Are you diagnosed with chronic graft versus host disease (cGVHD)? If so, you might be able to take part in a study to evaluate the safety and efficacy of belumosudil in combination with corticosteroids.

Age & Gender
  • 12 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Not currently enrolling

Improving chronic kidney disease in type 1 diabetes

This is a study for people with chronic kidney disease and type 1 diabetes. In this study, we want to learn more about the effectiveness and safety of a kidney drug called finerenone compared to a placebo.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Chronic Conditions
  • Kidneys and Liver
  • UNC Students (undergrad, grad, professional)
  • and 2 more
Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

EFFEKTOR Study for Kidney Transplant Recipents

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Kidneys and Liver
Open

Southern Liver Health Study

Have you ever wondered what environmental toxins you are exposed to on a daily basis, and how it might affect your health? The STRIVE study is looking for volunteers who would like to provide blood, urine, and/or saliva, as well as home samples such as soil, dust, and/or water. In this study, we want to learn more about the environmental factors that contribute to advanced liver disease and liver cancer. We are looking for healthy volunteers and people with liver cirrhosis who live in either North Carolina or Georgia to take part.

Age & Gender
  • 40 years ~ 75 years
  • Male, Female, Gender Inclusive
Study Interest
  • Environment
  • Kidneys and Liver
  • Wellness and Lifestyle
  • and 2 more
Not currently enrolling

A Phase II Study of CyBorD Plus Daratumumab for Patients with MGRS

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
  • Kidneys and Liver
Not currently enrolling

Financial Assistance Research

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Aging
  • Behavior
  • Blood Pressure
  • and 44 more
Visit Location
100% Remote (online, phone, text)
Open

Lupus Nexus Landmark Study: A Prospective Registry and Biorepository

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Chronic Conditions
  • Kidneys and Liver
  • Skin, Hair, and Nails
  • and 2 more
Open

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
  • Transplant
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research